Computational methods in drug design: Modeling G protein-coupled receptor monomers, dimers, and oligomers

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Reggio, Patricia H ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

GPCR dimer; GPCR modeling; GPCR oligomer

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DIMER; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; HETERODIMER; MONOMER; OLIGOMER; RHODOPSIN;

AB INITIO CALCULATION; BIOINFORMATICS; COMPUTER MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DIMERIZATION; DRUG DESIGN; DRUG MECHANISM; HUMAN; INTERNET; MATHEMATICAL COMPUTING; NONHUMAN; OLIGOMERIZATION; PREDICTION; PROTEIN DATA BANK; PROTEIN DATABASE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; DIMERIZATION; DRUG DESIGN; HUMANS; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 33646934650     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080237     Document Type: Review

References (123)

1. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002;520:97-101.
2. Kolakowski LF, Jr. GCRDb: a G-protein-coupled receptor database. Receptors Channels. 1994;2:1-7.
3. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999;18:1723-1729.
4. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-1272.
5. Eilers M, Hornak V, Smith SO, Konopka JB. Comparison of class A and D G protein-coupled receptors: common features in structure and activation. Biochemistry. 2005;44:8959-8975.
6. Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. In: Sealfon SC, Conn PM, eds. Methods in Neurnsciences. vol. 25. San Diego, CA: Academic Press; 1995:366-428.
7. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739-745.
8. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol. 2004;343:1409-1438.
9. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA. 2002;99:5982-5987.
10. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol. 2004;342:571-583.
11. Wess J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J. 1997;11:346-354.
12. Iiri T, Farfel Z, Bourne HR. G-protein diseases furnish a model for the turn-on switch. Nature, 1998;394:35-38.
13. Menon ST, Han M, Sakmar TP. Rhodopsin: structural basis of molecular physiology. Physiol Rev. 2001;81:1659-1688.
14. Lewis JW, Kliger DS. Photointermediates of visual pigments. J Bioenerg Biomembr. 1992;24:201-210.
15. Schertler GF. Structure of rhodopsin and the metarhodopsin I photointermediate. Curr Opin Struct Biol. 2005;15:408-415.
16. Bramblett RD, Panu AM, Ballesteros JA, Reggio PH. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci. 1995;56:1971-1982.
17. Ballesteros JA, Weinstein H. Analysis and refinement of criteria for predicting the structure and relative orientations of transmembranal helical domains. Biophys J. 1992;62:107-109.
18. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000;29:291-325.
19. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815.
20. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci. 2000;9:1753-1773.
21. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol. 2001;60:1-19.
22. Zhang R, Hurst DP, Barnett-Norris J, Reggio PH, Song ZH. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol Pharmacol. 2005;68:69-83.
23. Ballesteros JA, Deupi X, Olivella M, Haaksma EE, Pardo L. Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation. Biophys J. 2000;79:2754-2760.
24. Guarnieri F, Weinstein H. Conformational memories and the exploration of biologically relevant peptide conformations: an illustration for the gonadotropin-releasing hormone. J Am Chem Soc. 1996;118:5580-5589.
25. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta 2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem. 2002;277:40989-40996.
26. Barnett-Norris J, Hurst DP, Buehner K, Ballesteros JA, Guarnieri F, Reggio PH. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a Helix 6 active conformation. Int J Quantum Chem. 2002;88:76-86.
27. Eisenberg D, Weiss RM, Terwilliger TC. The hydrophobic moment detects periodicity in protein hydrophobicity. Proc Natl Acad Sci USA. 1984;81:140-144.
28. Komiya H, Yeates TO, Rees DC, Allen JP, Feher G. Structure of the reaction center from Rhodobacter sphaeroides R-26 and 2.4.1: symmetry relations and sequence comparisons between different species. Proc Natl Acad Sci USA. 1988;85:9012-9016.
29. Donnelly D, Johnson MS, Blundell TL, Saunders J. An analysis of the periodicity of conserved residues in sequence alignments of G-protein coupled receptors: implications for the three-dimensional structure. FEBS Lett. 1989;251:109-116.
30. Donnelly D, Overington JP, Ruffle SV, Nugent JH, Blundell TL. Modeling alpha-helical transmembrane domains: the calculation and use of substitution tables for lipid-facing residues. Protein Sci. 1993;2:55-70.
31. Baldwin J. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993;12:1693-1703.
32. Schertler GF, Villa C, Henderson R. Projection structure of rhodopsin. Nature. 1993;362:770-772.
33. Trabanino RJ, 3rd, Hall SE, 3rd, Vaidehi N, 3rd, Floriano WB, 3rd, Kam VW, 3rd, Goddard WA, 3rd. First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin. Biophys J. 2004;86:1904-1921.
34. Kalani MY, Vaidehi N, Hall SE, et al. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc Natl Acad Sci USA. 2004;101:3815-3820.
35. Freddolino PL, Kalani MY, Vaidehi N, et al. Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. Proc Natl Acad Sci USA. 2004;101:2736-2741.
36. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GF. Electron crystallography reveals the structure of metarhodopsin I. EMBO J. 2004;23:3609-3620.
37. Gether U, Kobilka BK. G protein-coupled receptors, II: mechanism of agonist activation. J Biol Chem. 1998;273:17979-17982.
38. Arnis S, Fahmy K, Hofmann KP, Sakmar TP. A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J Biol Chem. 1994;269:23879-23881.
39. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA. 2001;98:5997-6002.
40. Farrens D, Altenbach C, Ynag K, Hubbell W, Khorana H. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science. 1996;274:768-770.
41. Gether U, Lin S, Ghanouni P, Ballesteros J, Weinstein H, Kobilka B. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J. 1997;16:6737-6747.
42. 2 adrenergic receptor involves disruption of an ionic link between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem. 2001;276:29171-29177.
43. Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, Weinstein H. Structural motifs as functional microdomains in G-protein-coupled receptors: energetic considerations in the mechanism of activation of the serotonin 5-HT2a receptor by disruption of the ionic lock of the arginine cage. Int J Quantum Chem. 2002;88:65-75.
44. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem. 2001;276:9279-9290.
45. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem. 2004;279:48024-48037.
46. Gouldson PR, Kidley NJ, Bywater RP, et al. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor. Proteins. 2004;56:67-84.
47. Klein-Seetharaman J, Yanamala NV, Javeed F, et al. Differential dynamics in the G protein-coupled receptor rhodopsin revealed by solution NMR. Proc Natl Acad Sci USA. 2004;101:3409-3413.
48. Borhan B, Souto ML, Imai H, Shichida Y, Nakanishi K. Movement of retinal along the visual transduction path. Science. 2000;288:2209-2212.
49. Lin S, Sakmar T. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry. 1996;35:11149-11159.
50. Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F. Activation of the cannabinoid CB1 receptor may involve a W6.48/F3.36 rotamer toggle switch. J Pept Res. 2002;60:357-370.
51. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001;276:24433-24436.
52. Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol. 2005;67:2016-2024.
53. Paterlini MG. The function of the extracellular regions in opioid receptor binding: insights from computational biology. Curr Top Med Chem. 2005;5:357-367.
54. Tosatto SC, Bindewald E, Hesser J, Manner R. A divide and conquer approach to fast loop modeling. Protein Eng. 2002;15:279-286.
55. Xiang Z, Soto CS, Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc Natl Acad Sci USA. 2002;99:7432-7437.
56. Mehler EL, Periole X, Hassan SA, Weinstein H. Key issues in the computational simulation of GPCR function: representation of loop domains. J Comput Aided Mol Des. 2002;16:841-853.
57. Hassan SA, Mehler EL, Weinstein H. Structure calculation of protein segments connecting domains with defined secondary structure: a simulated annealing Monte Carlo combined with biased scaled collective variables technique. In: Schlick T, Gan HH, eds. Computational Methods for Macromolecules: Challenges and Applications. Vol 24. New York, NY: Springer Verlag; 2002:197-231.
58. Hassan SA, Guarnieri F, Mehler EL. A general treatment of solvent effects based on screened coulomb potentials. J Phys Chem B. 2000;104:6478-6489.
59. Chabre M, le Maire M. Monomeric G-protein-coupled receptor as a functional unit. Biochemistry. 2005;44:9395-9403.
60. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004;5:30-34.
61. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci. 2005;26:131-137.
62. Reddy PS, Corley RB. Assembly, sorting, and exit of oligomeric proteins from the endoplasmic reticulum. Bioessays. 1998;20:546-554.
63. Marshall FH, Jones KA, Kaupmann K, Bettler B. GABAB receptors - the first 7TM heterodimers. Trends Pharmacol Sci. 1999;20:396-399.
64. Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron. 2000;27:97-106.
65. Milligan G. Oligomerisation of G-protein-coupled receptors. J Cell Sci. 2001;114:1265-1271.
66. Roess DA, Smith SM. Self-association and raft localization of functional luteinizing hormone receptors. Biol Reprod. 2003;69:1765-1770.
67. Latif R, Graves P, Davies TF. Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor. J Biol Chem. 2002;277:45059-45067.
68. Terrillon S, Durroux. T, Mouillac B, et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol. 2003;17:677-691.
69. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K. Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature. 2003;421:127-128.
70. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem. 2003;278:21655-21662.
71. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999;399:697-700.
72. Galvez T, Duthey B, Kniazeff J, et al. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J. 2001;20:2152-2159.
73. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 2000;20:RC110.
74. Maggio R, Barbier P, Colelli A, Salvadori F, Demontis G, Corsini GU. G protein-linked receptors: pharmacological evidence for the formation of heterodimers. J Pharmacol Exp Ther. 1999;291:251-257.
75. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced finictional activity. Science. 2000;288:154-157.
76. Franco R, Ferre S, Agnati L, et al. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology. 2000;23:S50-S59.
77. Nelson G, Chandrashekar J, Hoon MA, et al. An amino-acid taste receptor. Nature. 2002;416:199-202.
78. Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS. Mammalian sweet taste receptors. Cell. 2001;106:381-390.
79. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 2001;20:2497-2507.
80. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 2000;407:94-98.
81. Gines S, Hillion J, Torvinen M, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA. 2000;97:8606-8611.
82. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001;276:14027-14036.
83. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67:1697-1704.
84. Hamm HE. How activated receptors couple to G proteins. Proc Natl Acad Sci USA. 2001;98:4819-4821.
85. Baneres JL, Parello J. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol. 2003;329:815-829.
86. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;275:7862-7869.
87. Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem. 2003;278:10770-10777.
88. Stanasila L, Perez JB, Vogel H, Cotecchia S. Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem. 2003;278:40239-40251.
89. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation. 2003;108:1611-1618.
90. Schulz A, Grosse R, Schultz G, Gudermann T, Schoneberg T. Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors. J Biol Chem. 2000;275:2381-2389.
91. Lee SP, O'Dowd BF, Ng GY, et al. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Mol Pharmacol. 2000;58:120-128.
92. Hamdan FF, Ward SD, Siddiqui NA, Bloodworth LM, Wess J. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor. Biochemistry. 2002;41:7647-7658.
93. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem. 1999;42:2105-2111.
94. Overton MC, Blumer KJ. The extracellular N-terminal domain and transmembrane domains 1 and 2 mediate oligomerization of a yeast G protein-coupled receptor. J Biol Chem. 2002;277:41463-41472.
95. Guo W, Shi L, Javitch JA. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem. 2003;278:4385-4388.
96. Guo W, Shi L, Filizola M, Weinstein H, Javitch JA. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA. 2005;102:17495-17500.
97. Gouldson PR, Higgs C, Smith RE, Dean MK, Gkoutos GV, Reynolds CA. Dimerization and domain swapping in G-protein-coupled receptors: a computational study. Neuropsychopharmacology. 2000;23:S60-S77.
98. Maggio R, Vogel Z, Wess J. Coexpression studies with mutant muscarinic/ adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc Natl Acad Sci USA. 1993;90:3103-3107.
99. Ridge KD, Lee SS, Abdulaev NG. Examining rhodopsin folding and assembly through expression of polypeptide fragments. J Biol Chem. 1996;271:7860-7867.
100. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science. 1988;240:1310-1316.
101. Schoneberg T, Liu J, Wess J. Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor. J Biol Chem. 1995;270:18000-18006.
102. Schoneberg T, Yun J, Wenkert D, Wess J. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J. 1996;15:1283-1291.
103. Gudermann T, Schoneberg T, Schultz G. Functional and structural complexity of signal transduction via G-protein-coupled receptors. Annu Rev Neurosci. 1997;20:399-427.
104. Nielsen SM, Elling CE, Schwartz TW. Split-receptors in the tachykinin neurokinin-1 system-mutational analysis of intracellular loop 3. Eur J Biochem. 1998;251:217-226.
105. Bakker RA, Dees G, Carrillo JJ, et al. Domain swapping in the human histamine H1 receptor. J Pharmacol Exp Ther. 2004;311:131-138.
106. Maggio R, Barbier P, Fornai F, Corsini GU. Functional role of the third cytoplasmic loop in muscarinic receptor dimerization. J Biol Chem. 1996;271:31055-31060.
107. Filizola M, Weinstein H. The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J. 2005;272:2926-2938.
108. Pazos F, Helmer-Citterich M, Ausiello G, Valencia A. Correlated mutations contain information about protein-protein interaction. J Mol Biol. 1997;271:511-523.
109. Gouldson PR, Dean MK, Snell CR, Bywater RP, Gkoutos G, Reynolds CA. Lipid-facing correlated mutations and dimerization in G-protein coupled receptors. Protein Eng. 2001;14:759-767.
110. Filizola M, Olmea O, Weinstein H. Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method. Protein Eng. 2002;15:881-885.
111. Filizola M, Weinstein H. Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers. 2002;66:317-325.
112. Olmea O, Valencia A. Improving contact predictions by the combination of correlated mutations and other sources of sequence information. Fold Des. 1997;2:S25-S32.
113. 1/ dopamine D2 heterodimer interfaces using correlated mutation analysis. 2005 Symposium on the Cannabinoids; June 24-27; Clearwater Beach, FL. Burlington, VT: International Cannabinoid Research Society; 2005. 101.
114. Lichtarge O, Bourne HR, Cohen FE. Evolutionarily conserved Galphabetagamma binding surfaces support a model of the G protein-receptor complex. Proc Natl Acad Sci.USA. 1996;93:7507-7511.
115. Lichtarge O, Bourne HR, Cohen FE. An evolutionary trace method defines binding surfaces common to protein families. J Mol Biol. 1996;257:342-358.
116. Lichtargc O, Yamamoto KR, Cohen FE. Identification of functional surfaces of the zinc binding domains of intracellular receptors. J Mol Biol. 1997;274:325-337.
117. Livingstone CD, Barton GJ. Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. Comput Appl Biosci. 1993;9:745-756.
118. Madabushi S, Gross AK, Philippi A, Meng EC, Wensel TG, Lichtarge O. Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions. J Biol Chem. 2004;279:8126-8132.
119. Chothia C, Lesk AM. The relation between the divergence of sequence and structure in proteins. EMBO J. 1986;5:823-826.
120. Koshi JM, Mindell DP, Goldstein RA. Using physical-chemistry-based substitution models in phylogenetic analyses of HIV-1 subtypes. Mol Biol Evol. 1999;16:173-179.
121. Koshi JM, Goldstein RA. Models of natural mutations including site heterogeneity. Proteins. 1998;32:289-295.
122. Koshi JM, Goldstein RA. Context-dependent optimal substitution matrices. Protein Eng. 1995;8:641-645.
123. Soyer OS, Dimmic MW, Neubig RR, Goldstein RA. Dimerization in aminergic G-protein-coupled receptors: application of a hidden-site class model of evolution. Biochemistry. 2003;42:14522-14531.